Exploring biomarkers for early detection of pancreatic tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify biomarkers that can predict the early carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the pancreas. It will involve the prospective enrollment of patients diagnosed with IPMN, who will provide biological samples such as blood, urine, feces, and saliva for analysis. The study focuses on utilizing multi-omics approaches to assess the predictive accuracy of these biomarkers for malignant transformation of IPMN. Secondary endpoints include evaluating surgical resection rates and survival outcomes post-surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* clinically diagnosed as IPMN;
* without other malignant tumor;
* agree to sign informed consent.

Exclusion Criteria:

* with mental disorders which can affect cognition and cooperation;
* with serious blood diseases or taking drugs that can affect peripheral blood

Where it's running

• the First Affiliated Hospital, School of Medicine, Zhejiang University
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Tingbo Liang, PhD
• Email: liangtingbo@zju.edu.cn
• Phone: +86 19941463683

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood protein biomarkers to help diagnose pancreatic cancer in adults

  This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.

  Recruiting Grigore T. Popa University of Medicine and Pharmacy · Iași · NCT07875582

• Liquid biopsy biomarkers to detect and monitor pancreatic cancer

  Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.

  Recruiting Università Vita-Salute San Raffaele · Milan, MI · NCT07700992

• Why surgery was performed for IPMN and the outcomes

  This project looks at medical records of adults who had surgery for IPMN to see if operations were done for suspected cancer versus incidental findings and how those patients did afterward.

  Recruiting at 14 sites NYU Langone Health · Phoenix, Arizona and 13 other locations · NCT07216521

• AI-enhanced low-dose CT to screen for pancreatic cancer

  This project will test whether an AI tool called PANDA can read low-dose CT scans to find early pancreatic cancer in people aged 50 and older.

  Recruiting at 5 sites Changhai Hospital · Shanghai, Shanghai Municipality and 4 other locations · NCT07117045

• AI-based early detection of pancreatic cancer using routine CT scans

  This study is testing an AI system that uses regular CT scans to see if it can help find pancreatic cancer early in people who are at high risk.

  Recruiting at 3 sites Changhai Hospital · Shanghai, Shanghai Municipality and 2 other locations · NCT06638866

• Registry for pancreatic cysts at UCSF

  This study is setting up a registry to track patients with pancreatic cysts to see how these cysts change over time and to help doctors make better treatment decisions.

  Recruiting University of California, San Francisco · San Francisco, California · NCT04291651

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.